Tech Company Inital Public Offerings

Axcella Health IPO

Axcella Health was acquired by . Shares were listed on 5/8/2019.

Transaction Overview

Company Name
Announced On
5/8/2019
Transaction Type
IPO
Amount
$72,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds and existing cash on hand as follows: approximately $90.0 million to advance our current liver (AXA1665, AXA1125 and AXA1957) and other programs, including through additional Non-IND, IRB-Approved Clinical Studies, potential IND filing(S) and the ensuing Clinical Trials, including our planned IND filing and Clinical Trial for AXA1665, and infrastructure to support our pipeline; approximately $30.0 million to advance our AXA Development Platform discovery efforts, intellectual property and associated infrastructure; and the remainder, if any, for working capital and other general corporate purposes.

Company Information

Company Status
Publicly-held
Industry
Consumer
Mailing Address
840 Memorial Dr.
Cambridge, MA 02139
USA
Email Address
Not Recorded
Overview
Axcella Health (Nasdaq: AXLA) is a pioneer in developing transformative medicines for patients with diseases in which disrupted amino acid biology plays a central role.
Profile
Axcella Health LinkedIn Company Profile
Social Media
Axcella Health Company Twitter Account
Company News
Axcella Health News
Facebook
Axcella Health on Facebook
YouTube
Axcella Health on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Connelly
  Robert Connelly LinkedIn Profile  Robert Connelly Twitter Account  Robert Connelly News  Robert Connelly on Facebook
Chief Financial Officer
Thomas Leggett
  Thomas Leggett LinkedIn Profile  Thomas Leggett Twitter Account  Thomas Leggett News  Thomas Leggett on Facebook
Chief Information Officer
David Berry
  David Berry LinkedIn Profile  David Berry Twitter Account  David Berry News  David Berry on Facebook
Chief Medical Officer
Manu Chakravarthy
  Manu Chakravarthy LinkedIn Profile  Manu Chakravarthy Twitter Account  Manu Chakravarthy News  Manu Chakravarthy on Facebook
VP - Bus. Development
Ivana Magovcevic-Liebisch
  Ivana Magovcevic-Liebisch LinkedIn Profile  Ivana Magovcevic-Liebisch Twitter Account  Ivana Magovcevic-Liebisch News  Ivana Magovcevic-Liebisch on Facebook
VP - R & D
Michael Hamill
  Michael Hamill LinkedIn Profile  Michael Hamill Twitter Account  Michael Hamill News  Michael Hamill on Facebook
VP - R & D
Tony Tramontin
  Tony Tramontin LinkedIn Profile  Tony Tramontin Twitter Account  Tony Tramontin News  Tony Tramontin on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/8/2019: Elligo Health Research venture capital transaction
Next: 5/8/2019: Greyrock Energy venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to record tech company VC transactions. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary